Brace AD, Evans WJ, Glass DJ, Russell AJ. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells.
INSULIN-LIKE GROWTH FACTOR I (IGF-1) is an important mediator of muscle growth and repair (22) . The Igf1 gene spans six exons and can give rise to several mRNA variants by differential promoter usage and alternative splicing (4) . The circulating form of IGF-1 comprises a 70-amino acid NH 3 -terminal protein, which has had a COOH-terminal peptide downstream of amino acid 70 cleaved. The mature protein will be referred to here as "IGF-1." In skeletal muscle, full-length, uncleaved IGF-1 has been observed by Western blot (12) , suggesting the possibility that full-length, uncleaved splice forms may have distinct functions. Two members of this family of splice variants contain a sixth COOH-terminal exon, designated IGF1Ea and IGF-1Eb in rodents. IGF-1Eb is named IGF-1Ec in humans (4) . Rodent muscles exposed to stretch, exercise, or injury demonstrate an acute, transient elevation of IGF-1Eb, followed by a later expression of IGF-1Ea (13, 14) . Similar results have also been obtained after lengthening contractions in human volunteers (19) . As a result of the acute response of IGF-1Eb/c to muscle damage, it is often and somewhat confusingly referred to as mechano-growth factor (MGF); this is confusing because this MGF name has also been given to the COOH-terminal peptide alone, which is divorced from IGF-1. We will refer to the full-length unspliced forms as IGF-1Ea, IGF-1Eb, and IGF-1Ec and the COOH-terminal 24-amino acid peptide as "MGF." IGF-1Eb/c can be detected intact in liver extracts from various sources (27) .
Several studies have ascribed an IGF-1-independent role for MGF in the muscle regenerative process. Addition of MGF peptide to C 2 C 12 muscle myoblasts increased proliferation and retarded differentiation, even in the presence of anti-IGF-I receptor antibodies (31) . Similar proliferation/differentiation results were also obtained in studies with primary human muscle myoblasts derived from explant cultures (2) and with porcine satellite cells (25) . MGF also has a documented role in enhancing human muscle myoblast migration, possibly through activating matrix fibrinolytic and metalloproteinase systems (21) . Beyond muscle, MGF has been proposed as a neuroprotective factor. Intracarotid injection of MGF peptide reduced cell death in a gerbil model of ischemic damage and protected neuronal death after neurotoxic stress in vitro and in vivo (10, 26) . Additional roles for the MGF peptide have also been documented for prostate cancer and endometrial cell proliferation (1, 20) and as a cardioprotective factor during ischemic damage (8) .
Poor recovery from muscle damage is a prominent feature of several neuromuscular disorders, including muscular dystrophy and the frailty associated with old age, leading to excessive muscle fibrosis and reduced function (16) . Based on its published preclinical activities, MGF represents a promising therapeutic agent to enhance the speed and efficiency of muscle regeneration. Our two laboratories independently decided to test some of the reported functions of MGF in C 2 C 12 cells, primary human muscle myoblasts and primary mouse muscle stem cells, and indeed the data contained herein represents an even larger effort, spanning three companies and four research groups. Although we observed robust responses to IGF-1 and the IGF-1Eb/c splice form, neither of our laboratories could find biological activity of a purified MGF peptide, nor could either laboratory demonstrate a differentiated response between the IGF-1 and IGF-1Eb/c, suggesting that IGF-1 was sufficient for the biological responses observed in these cells. Although we cannot rule out a distinct role for the IGF-1Eb isoform in muscle repair, these data question whether the discrete MGF peptide has any physiological role in this process.
EXPERIMENTAL PROCEDURES
CELLS AND MATERIALS. C2C12 cells were obtained from American Type Culture collection (ATCC). Human skeletal muscle cells (HuSkMC) were obtained from Cambrex, and Lonza Mouse monoclonal antibody against myosin heavy chain (MHC; clone A4.1025) was purchased from Upstate. APC-conjugated antibodies to CD11b, CD45, CD31, SCA-1, and TER119 were purchased from eBioscience, anti-CD34-PE antibody (RAM34) was purchased from BD Biosciences, and anti-ITGA7-FITC was purchased from R & D Systems. The ALK4/5 inhibitor compound GW-849825X was synthesized as described in a published patent (11) Cell culture. C 2C12 cells were grown in growth medium (GM) consisting of Dulbecco's modified Eagle's medium (DMEM; 1:1 mixture of nos. 41965-039 and 42430-025; Invitrogen) supplemented with 10% fetal calf serum (FCS; Amimed), 1% penicillinstreptomycin (Invitrogen), and 1% glutamine (Invitrogen) at 37°C, 5% CO 2, and 95% humidity. Human skeletal muscle cells (HuSkMC; Lonza) were cultured on Matrigel (BD Bioscience) in GM consisting of skeletal muscle basal medium (Lonza) supplemented with 20% fetal calf serum. To obtain human primary myotubes, cells were seeded onto six-well plates in GM at a density of 0.15 ϫ 10 6 cells/well. Differentiation was initiated 24 h after seeding by changing to serum-free differentiation medium (DM) consisting of skeletal muscle basal medium plus 0.5% gentamycin (Invitrogen) and 0.1 mM SB-431542 (Sigma) for 4 days. Mouse satellite cells were isolated using a modification of existing protocols, using limb muscle from C57BL/6 mice (9, 23). Briefly, collagenase IV/dispase digestion of limb muscle was processed in a GentleMACS (Miltenyi), using program B and C tubes. Muscle-associated cells were collected by centrifugation and labeled with antibodies to CD11b, CD45, CD31, SCA-1, and TER119 plus anti-CD34-PE and anti-ITGA7-FITC. After free antibody was washed away, cells were labeled with anti-APC magnetic beads (Miltenyi) and then passed over LD magnetic columns (Miltenyi) to remove APC labeled cells. The depleted cell mixture was then collected by centrifugation and stained with propidium iodide and calcein blue AM prior to cell sorting on a BD Biosciences ARIA II. Live, APCϪ, CD34ϩ, and ITGA7ϩ cells were isolated and cultured in F10 (Invitrogen) supplemented with 20% heat-inactivated horse serum (Invitrogen), penicillin-streptomycin, and 10 ng/ml basic fibroblast growth factor. Cells were cultured in 384-well tissue culture plates coated with rat tail collagen (1 g/ml) and mouse laminin (10 g/ml). Neonatal Sprague-Dawley rat ventricular myocytes (NRVM) were prepared from minced heart pieces by pancreatin enzyme digestion and high-density Percoll isolation (3). Primary cells were also purchased (Lonza). Tissue collection for both satellite cell and ventricular myocyte preparations was performed in accordance with Animal Use Protocol nos. 2010-3-10 (FivePrime Therapeutics) and PA-AUP0216 (GlaxoSmithKline) and reviewed and approved by both institutes' Institutional Animal Care and Use Committees.
Proliferation assays. For proliferation assays with C2C12, cells were plated onto 96-well plates at a density of 2 ϫ 10 3 /well and cultured in GM containing 1% FCS for 72 h. Cells were then starved for 12 h in the absence of serum and stimulated with the specified peptides for 24 h. Bromodeoxyuridine (10 M) was added during the last 4 h of the 24-h stimulation. For proliferation assays with HuSkMC (Lonza), cells were plated onto 96-well plates at a density of 5 ϫ 10 3 /well and cultured in GM supplemented with growth factors or MGF peptides for 48 h. Cells were then quantified using a CellTiterGlo Luminescent Cell Viability Assay (Promega). Proliferation assays with primary mouse skeletal muscle stem cells were performed by seeding at 250 cells/well in 384-well plates. Growth factors and peptides were added 16 h after plating the cells, and the plates were then incubated at 37°C for 6 days. Cells were then fixed with paraformaldehyde, and DAPI -stained nuclei were counted on a Becton-Dickinson Pathways 420 microscope.
Fusion assay and myotube size analysis. For fusion assays with C2C12 myoblasts, cells were seeded onto six-well plates in GM at a density of 10 5 cells/well and grown at 37°C for 3 days. Cells were washed once with DM consisting of DMEM supplemented with 1% heat-inactivated horse serum (Cambrex), 1% penicillin-streptomycin, and 1% glutamine and then incubated in DM for 48 -72 h at 37°C, 5% CO2, and 95% humidity with the indicated peptides. Myotubes were washed with cytoskeleton-stabilizing buffer (CSB) consisting of 80 mM PIPES, 5 mM EGTA, 1 mM MgCl2, and 40 g/l PEG35000 in distilled water (pH 7.4) and fixed with 4% paraformaldehyde in CSB for 15 min at room temperature. Cells were then permeabilized with 0.2% Triton in CSB, and nonspecific binding was blocked with normal goat serum (Zymed), followed by incubation with anti-MHC antibody diluted in PBS and subsequently with Alexa Fluor 488 F (AB=) diluted in PBS. Cells were then mounted with ProLong Gold antifade reagent with DAPI (Invitrogen). Fusion index was calculated as follows: MHC-positive myotubes were segmented according to Table 1 .
Peptide Sequence
Human MGF Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys Human MGF stabilized Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-D-Arg-D-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys Human MGF Goldspink Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys Human MGF Goldspink stabilized Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-D-Arg-D-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys Mouse MGF Ser-Pro-Ser-Leu-Ser-Thr-Asn-Lys-Lys-Thr-Lys-Leu-Gln-Arg-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu MGF, mechano-growth factor. 6 /well and cultured in DMEM-M199 (3:1 mixture; Gibco) with 15% FCS (Hyclone), penicillin-streptomycin (100 U/ml), and 2 mM L-glutamine at 37°C, 5% CO 2, and 95% humidity. After 24 h, cells were washed in PBS and serum starved in 2 ml/well DMEM-M199 media minus FCS for 24 h. rhIGF-1 (no. 4326-RG; R & D Systems), MGF (no. 033-35; Phoenix Pharmaceuticals), or MGF (Genscript) was added to wells. At indicated time points, plates were chilled on ice and media thoroughly decanted, and 200 l of lysis buffer was added (Bio-Rad). Cells were disrupted with a scraper, and the plate was stored at Ϫ80°C. Plates were thawed and scraped and lysates carefully collected and spun at 12,000 rpm ϫ 10 min. The supernatant was collected and protein determined by BCA protein assay (no. 23221; Thermo Scientific). Samples were normalized to ϳ0.3 mg/ml and diluted 1:1 with Bio-Rad phosphoprotein assay buffer (no. 171-304004). Normalized lysates were incubated with Bio-Plex phosphoprotein custom 8-plex beads containing p-AKT, p-GSK-3␣/␤, p-p70 S6, p-c-jun, p-ERK1/2, p-JNK and p-p38 MAPK according to the manufacturer's protocol.
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Statistical analysis. Statistical significance was evaluated with one-way analysis of variance for multiple groups, followed by Bonferroni's or Tukey's post hoc test to evaluate differences among groups.
RESULTS
We first tested the effect of MGF on cell proliferation and differentiation in C 2 C 12 muscle myoblasts (Fig. 1) . There have been two sequence variants of MGF described in the literature, the native human sequence and a consensus sequence derived from multiple species (10), as illustrated in Table 1 . Further modifications where MGF peptide has been stabilized by the substitution of naturally occurring L-arginine for the D-form of this amino acid have also been detailed (10, 15, 26) . Proliferation was measured with stabilized and native forms of the two MGF sequences and compared with the mature IGF-1 peptide (Fig. 1A) . Whereas mature IGF-1 doubled cell number at the highest concentration tested, no MGF peptide tested enhanced cell proliferation. C 2 C 12 differentiation was then measured by quantifying the number of nuclei per cell after 2-3 days in differentiation media (Fig. 1B) . Mature IGF-1 enhanced cell fusion, which was reflected by an increase in the observed nuclei per myotube, whereas MGF did not alter cell fusion.
MGF has also been shown to increase the proliferation of primary human muscle myoblasts (2) while both reduced and enhanced differentiation have been observed in these cells (2, 15) . We measured the effect of MGF on human skeletal muscle myoblast proliferation. Similar to data obtained with C 2 C 12 cells, a surrogate of proliferation (measuring ATP concentration) was not altered by either form of the MGF peptide ( Fig. 2A) . Three-day differentiated myotubes were then treated for 24 h with IGF-1, IGF-1Ec, MGF, and a scrambled peptide. As shown in Fig. 2B , IGF-1 and IGF-1Ec treatment led to a significant increase in myotube diameter compared with vehicle control. However, we found that MGF did not affect myotube size at any tested concentration (Fig. 2C) .
Although the use of C 2 C 12 and human skeletal muscle myoblast cell lines in muscle research commonly predicts biology in primary muscle, the ability of these cells to transdifferentiate to adipogenic cells may not reflect the exact phenotype of primary muscle stem cells (28, 30) . We tested whether native MGF, IGF-1, or IGF-1Ec could increase cell Fig. 1 . Effect of human mechano-growth factor (MGF) on C2C12 proliferation and differentiation. A: C2C12 myoblasts were cultured as described in EXPERIMENTAL PROCEDURES, starved for 12 h, and stimulated with the indicated human peptides for 24 h. The proliferation rate was monitored by bromodeoxyuridine (BrdU) incorporation. B: C2C12 myoblasts were cultured in differentiation medium for 48 -72 h with the indicated growth factors or human MGF peptides. Myotubes were fixed and stained with an antibody to myosin heavy chain (MHC), and fusion index was analyzed as described in EXPERIMENTAL PROCEDURES.
proliferation in primary quiescent skeletal muscle stem cells isolated from mice. An ALK4/5 inhibitor compound, GW-849825X, was included as a positive control, as ALK4/5 inhibition is known to increase proliferation of skeletal muscle progenitor cells (Fig. 3A) (7) . Six days of exposure to IGF-1, IGF-1Ec, or GW-849825X resulted in significantly more cells compared with vehicle wells, whereas human and mouse MGF-treated wells were no different from vehicle control. We next tested the effect of MGF, IGF-1, IGF-1Ec, and GW-849825X on differentiation of primary muscle stem cells. IGF-1, IGF-1Ec, and GW-849825X increased both the overall number of myotubes (Fig. 3B ) and the total myotube area per well (Fig. 3C) , with a similar response between IGF-1 and IGF-1Ec. MGF had no apparent effect on the number or size of these cells.
Finally, we explored a separate function of MGF in the myocardial repair process (8, 29) . We incubated primary neonatal rat ventricular myocytes with native and stabilized MGF and examined signal transduction (Fig. 4, A-F) .
Whereas control mature IGF-1 stimulated Akt, ERK, and p70 S6K phosphorylation at 15 and 30 min (only 15 min shown), neither form of MGF peptide increased phosphorylation of any marker. Stabilized MGF transiently decreased p-ERK, returning to baseline levels at 30 min (data not shown).
DISCUSSION
The regenerative protective profile of MGF on muscle is an appealing one for scientists involved in drug discovery. The data shown in this article represent efforts that span four separate research groups over three companies (GlaxoSmithKline Muscle Metabolism and Heart Failure Discovery Performance Units, Novartis, and FivePrime Therapeutics). To date, none of these aggregated efforts have succeeded in assigning a distinct function to the various forms of the COOH-terminal IGF-1Eb/c peptides. Myotubes were fixed and stained with an antibody to MHC, and analysis of myotube diameter was performed as described in EXPERIMENTAL PROCEDURES. Shown are means Ϯ SE of a representative experiment (n ϭ 2). ***P Ͻ 0.05; ****P Ͻ 0.0001 vs. vehicle control. WT, wild type; ctrl, control. Fig. 3 . Effect of MGF on primary skeletal muscle stem cells. A: cells were plated as described and peptides added after 16h growth was quantified, with a nucleus count 6 days later. B and C: cells were grown and then differentiated for 2 days with the indicated peptides. Myotubes were fixed and stained with an antibody to MHC and analyzed for total myotube no. and total myotube area, as described in EXPERIMENTAL PROCEDURES. Shown are means Ϯ SE of a representative experiment (n ϭ 14). **P Ͻ 0.05; ***P Ͻ 0.0001 vs. vehicle control.
Recent reports have brought into question the existence of a distinct IGF-1E peptide in vivo (18) , and the same group also disputed the ability of MGF peptides to induce proliferation of C 2 C 12 cells (17) . Although it is possible that a cleaved IGF-1E peptide exists and has biological activity in vivo, we find no evidence for an in vitro activity of these peptides in multiple human or mouse muscle myoblast lineages, including C 2 C 12 , HuSkMCs (from both Lonza and Cell Applications), and primary mouse muscle stem cells. At this moment, we are not certain why our collected data do not reproduce previous reports using C 2 C 12 cells (31) . It is always possible that the phenotype or culture conditions of these cells were distinct from our ATCC stocks of C 2 C 12 cells. Because of the inherent variability and questions regarding the exact lineage of immortalized myoblast lines, we extended our experiments with primary muscle stem cells. These cells also failed to reveal a distinct function for MGF peptides in either the proliferation or differentiation of these cells. Recent data with primary porcine satellite cells revealed a distinct bell-shaped dose response with higher concentrations of MGF inhibiting proliferation (25) . In separate experiments, we also tested concentrations of MGF as low as 1 nM on primary mouse stem cells. All concentrations yielded similar negative results (data not shown).
Our efforts also included experiments intended to recapitulate other features of MGF action such as proliferative effects on cardiomyocytes (29) . In these experiments, we used primary cells rather than tissue culture lines, which could be a source of disconnect for these data. We also attempted to reproduce reports of proliferation with MGF peptides in pc3 prostate cancer cell lines (1) and neuroprotection in SH-SY5Y human neuronal cells (26) . These also failed to recapitulate a unique biological activity of the peptides (data not shown).
Although we failed to reveal a distinct biological activity for purified MGF peptides compared with mature IGF-I in our assays, intriguing recent data argue for distinct features of the pro-IGF-I forms compared with mature IGF-I peptide. Viral transduction of mouse muscle with mature IGF-I, IGF-1Ea, or IGF-1Eb revealed a hypertrophic response, with only the pro-IGF-I complexes and partially overlapping transcriptional signatures of response between the three forms (6) . Viral delivery of IGF-1Ea and -Eb also appears to elicit a differential hypertrophic response with age (5). It is also possible that although we failed to identify a distinct function for MGF peptides, they might function in other contexts that we have not interrogated. For instance, transfection of C 2 C 12 cells with vectors encoding the Ea or Eb terminal extensions of IGF-I improved IGF-I uptake into untransfected cells, suggesting an extracellular role for these expressed peptides (24) . Presumably, such a function would not be independent of IGF-IR, unlike other claims for purified MGF peptides.
There have over the years been published comments questioning why negative data are not commonly published in the literature. The simple answer is that although a positive result demonstrating a unique activity is convincing, one is always left somewhat unsatisfied by a failure to show a claimed activity; there are always multiple potential reasons why an experiment may not have worked. This sort of concern is substantially relieved here because of the robust positive control data with mature IGF-I demonstrating that the systems used were operational and that the scientists were competent to perform the experiments. This leaves only the MGF itself as a potential source of concern, again relieved in this case by multiple batches tried and produced by distinct laboratories. Still, after all of these efforts, one cannot be absolute in claiming a negative result. But we can at least claim that after quite a significant effort, we can confirm none of the claimed unique biological effects of MGF so far. In conclusion, we failed to reveal a distinct biological activity for purified MGF peptides in multiple different cell model systems, indicating that there is no apparent role for a secreted MGF peptide in myoblast and satellite cell function.
